Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity
Open accessAbstract
BACKGROUND: Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors. METHODS: Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a measure of factor Xa inhibition by the anticoagulant. RESULTS: Among the apixaban-treated participants, anti-factor Xa activity was reduced by 94% among those who received an andexanet bolus (24 participants), as compared with 21% among those who received placebo (9 participants) (P<0.001), and unbound apixaban concentration was reduced by 9.3 ng per milliliter versus 1.9 ng per milliliter (P<0.001); thrombin generation was fully restored in 100% versus 11% of the participants (P<0.001) within 2 to 5 minutes. Among the rivaroxaban-treated participants, anti-factor Xa activity was reduced by 92% among those who received an andexanet bolus (27 participants), as compared with 18% among those who received placebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per milliliter versus 4.2 ng per milliliter (P<0.001); thrombin generation was fully restored in 96% versus 7% of the participants (P<0.001). These effects were sustained when andexanet was administered as a bolus plus an infusion. In a subgroup of participants, transient increases in levels of d-dimer and prothrombin fragments 1 and 2 were observed, which resolved within 24 to 72 hours. No serious adverse or thrombotic events were reported. CONCLUSIONS: Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects. (Funded by Portola Pharmaceuticals and others; ANNEXA-A and ANNEXA-R ClinicalTrials.gov numbers, NCT02207725 and NCT02220725.).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Andexanet alpha reverses the anticoagulant activity of apixaban and rivaroxaban in healthy probands within minutes after administration and for the duration of infusion, with a transient increase in markers of coagulation activity of uncertain clinical relevance.
“Andexanet alpha, a modified recombinant human factor Xa that lacks enzymatic activity, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy probands within minutes after administration and for the duration of infusion, with a transient increase in markers of coagulation activity of uncertain clinical relevance.508”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [508]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430 · see citing works
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943 · see citing works
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164 · see citing works
Idarucizumab for Dabigatran Reversal
Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502000 · Cited by 1,552 · see citing works
Idarucizumab for dabigatran reversal
Garrett, A. D., PharmD, & Bcps (2015) · Cited by 1,169 · see citing works
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K. Y., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 700 · see citing works
Self-citationProbability Tables for Individual Comparisons by Ranking Methods
Wilcoxon, F. (1947) · Biometrics · doi:10.2307/3001946 · Cited by 578 · see citing works
MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation
Lu, Y., Zhang, Y., Wang, N., Pan, Z., Gao, X., Zhang, F., Zhang, Y., Shan, H., Luo, X., Bai, Y., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.958967 · Cited by 450 · see citing works
Beyer‐Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C. U., Werth, S., Şahin, K., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563577 · Cited by 407 · see citing works
Pernod, G., Albaladejo, P., Godiér, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A. A., Llau, J. V., et al. (2013) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 307 · see citing works
Optimally weighted, fixed sequence and gatekeeper multiple testing procedures
Westfall, P. H., & Krishen, A. (2001) · Journal of Statistical Planning and Inference · doi:10.1016/s0378-3758(01)00077-5 · Cited by 240 · see citing works
Chowdary, P., Lethagen, S., Friedrich, U., Brand, B., Hay, C. R. M., Karim, F. A., Klamroth, R., Knöbl, P., Laffan, M., Mahlangu, J. N., et al. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12864 · Cited by 229 · see citing works
Held, C., Hylek, E. M., Alexander, J. H., Hanna, M., Lópes, R. D., WOJDYLA, D. M., Thomas, L. E., Al‐Khalidi, H. R., Alings, M., Xavier, D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu463 · Cited by 173 · see citing works
Tamayo, S. G., Peacock, W. F., Patel, M. R., Sicignano, N., Hopf, K. P., Fields, L. E., Sarich, T. C., Wu, S., Yannicelli, D., & Yuan, Ž. (2015) · Clinical Cardiology · doi:10.1002/clc.22373 · Cited by 152 · see citing works
Crowther, M., Manasar.Vandana, M., Kitt, M., Lu, G., Conley, P. B., Hollenbach, S. J., Castillo, J., Hutchaleelaha, A., Karbarz, M. J., Lin, J. P., et al. (2013) · Blood · doi:10.1182/blood.v122.21.3636.3636 · Cited by 115 · see citing works
Self-citationCrowther, M. A., Levy, G. G., Lu, G., Leeds, J. M., Lin, J. P., Pratikhya, P., Conley, P. B., Connolly, S. J., & Curnutte, J. T. (2014) · Blood · doi:10.1182/blood.v124.21.4269.4269 · Cited by 93 · see citing works
Self-citationRecombinant Antidote for Reversal of Anticoagulation by Factor Xa Inhibitors.
Lu, G., DeGuzman, F. R., Lakhotia, S., Hollenbach, S. J., Phillips, D. R., & Sinha, U. (2008) · Blood · doi:10.1182/blood.v112.11.983.983 · Cited by 45 · see citing works
Self-citationCrowther, M. A., Lu, G., Conley, P. B., Leeds, J. M., Castillo, J., Levy, G. G., Connolly, S. J., & Curnutte, J. T. (2014) · Critical Care Medicine · doi:10.1097/01.ccm.0000457952.01186.20 · Cited by 39 · see citing works
Self-citationVitamin K deficiency and D-dimer levels in the intensive care unit: a prospective cohort study
Crowther, M. A., McDonald, E., Johnston, M., & Cook, D. (2002) · Blood Coagulation & Fibrinolysis · doi:10.1097/00001721-200201000-00007 · Cited by 31 · see citing works
Self-citationBytniewski, P., Machała, W., Romanowski, L., Wiśniewski, W., & Kosowski, K. (2014) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-014-0089-0 · Cited by 26 · see citing works
Omote, M., Asakura, H., Takamichi, S., Shibayama, M., Yoshida, T., Kadohira, Y., MAEKAWA, M., Yamazaki, M., Morishita, E., Nakao, S., et al. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.05.008 · Cited by 20 · see citing works
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Luan, P., Abe, K. Y., Siu, G., Conley, P. B., Phillips, D. R., & Sinha, U. (2010) · Circulation · Cited by 10 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 5
- Crowther M, Lu G, Conley PB, et al. Reversal of factor Xa inhibitors-induced The New England Journal of Medicine Downloaded from nejm.org on September 26, 2023. For personal use only. No other uses without permission. Copyright © 2015 Massachusetts Medical Society. All rights reserved. n engl j med 373;25
- nejm.org December 17, 2015 2424 Andexanet for Reversal of Factor Xa Inhibitor Activity receive immediate notification when an article is published online first To be notified by e-mail when Journal articles are published Online First, sign up at NEJM.org. anticoagulation in healthy subjects by an- dexanet alfa. Crit Care Med 2014; 42(12): A1469.
- Rose M, Beasley B. Apixaban clinical review addendum. Silver Spring, MD: Cen- ter for Drug Evaluation and Research, 2012 (http://www .accessdata .fda .gov/ drugsatfda _docs/ nda/ 2012/ 202155Orig1s000MedR .pdf).
- Beasley N, Dunnmon P, Rose M. Riva- roxaban clinical review: FDA draft brief- ing document for the Cardiovascular and Renal Drugs Advisory Committee, 2011 (http://www .fda .gov/ downloads/ Advisory Committees/ CommitteesMeetingMaterials/ drugs/ CardiovascularandRenalDrugs AdvisoryCommittee/ ucm270796 .pdf).
- Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran rever- sal. N Engl J Med 2015; 373: 511-20.
Cited by
Sorted by citations
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P. F., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellà, M., Diener, H., Heidbüchel, H., Hendriks, J., et al. (2016) · EP Europace · doi:10.1093/europace/euw295 · Cited by 6,438 · see citing works
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418 · see citing works
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000923 · Cited by 3,686 · see citing works
Calkins, H. G., Hindricks, G., Cappato, R., Kim, Y., Saad, E., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, A. J., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.05.012 · Cited by 2,770 · see citing works
January, C. T., Wann, L. S., Calkins, H., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000665 · Cited by 2,744 · see citing works
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000932 · Cited by 2,449 · see citing works
January, C. T., Wann, L. S., Calkins, H. G., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.011 · Cited by 2,237 · see citing works
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.018 · Cited by 2,073 · see citing works
Rossaint, R., Bouillon, B., Černý, V., Coats, T., Duranteau, J., Fernández‐Mondejar, E., Filipescu, D. C., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,475 · see citing works
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403 · see citing works
Spahn, D. R., Bouillon, B., Černý, V., Duranteau, J., Filipescu, D. C., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,273 · see citing works
Hankey, G. J. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,248 · see citing works
Calkins, H. G., Hindricks, G., Cappato, R., Kim, Y., Saad, E., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, A. J., et al. (2017) · EP Europace · doi:10.1093/europace/eux274 · Cited by 1,191 · see citing works
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H. M., Krieger, E. V., Mack, M. J., McLeod, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.035 · Cited by 1,104 · see citing works
Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update
An, S. J., Kim, T. J., & Yoon, B. W. (2017) · Journal of Stroke · doi:10.5853/jos.2016.00864 · Cited by 1,020 · see citing works
Deep vein thrombosis and pulmonary embolism
Nisio, M. D., van Es, N., & Buller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 1,014 · see citing works
Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Crowther, M. A., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Lawrence, J. H., Yue, P., Bronson, M. D., Lu, G., Conley, P. B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814051 · Cited by 969 · see citing works
Self-citationAndexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Milling, T. J., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Gold, A., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P. B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607887 · Cited by 804 · see citing works
Self-citationManagement of severe perioperative bleeding
Kozek‐Langenecker, S. A., Ahmed, A. B., Afshari, A., Albaladejo, P., Aldecoa, C., Barauskas, G., ROBERTIS, E. D., Faraoni, D., Filipescu, D. C., Fries, D. R., et al. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000630 · Cited by 801 · see citing works
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · EP Europace · doi:10.1093/europace/euae043 · Cited by 689 · see citing works
Andrade, J. G., Aguilar, M., Atzema, C. L., Bell, A., Cairns, J. A., Cheung, C. C., Cox, J. L., Dorian, P., Gladstone, D. J., Healey, J. S., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.09.001 · Cited by 568 · see citing works
Chao, T., Joung, B., Takahashi, Y., Lim, T. W., Choi, E., Chan, Y., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0041-1739411 · Cited by 474 · see citing works
Doherty, J. U., Gluckman, T. J., Hucker, W. J., Januzzi, J. L., Ortel, T. L., Saxonhouse, S. J., & Spinler, S. A. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.024 · Cited by 445 · see citing works
Kamel, H., & Healey, J. S. (2017) · Circulation Research · doi:10.1161/circresaha.116.308407 · Cited by 435 · see citing works
January, C. T., Wann, L. S., Calkins, H. G., Chen, L. Y., Cigarroa, J. E., Cleveland, J. C., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., Furie, K. L., et al. (2019) · Heart Rhythm · doi:10.1016/j.hrthm.2019.01.024 · Cited by 409 · see citing works
Mazzolai, L., Aboyans, V., Ageno, W., Agnelli, G., Alatri, A., Bauersachs, R., Brekelmans, M. P. A., Büller, H. R., Elias, A., Farge, D., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx003 · Cited by 402 · see citing works
2017 EACTS Guidelines on perioperative medication in adult cardiac surgery
Sousa‐Uva, M., Head, S. J., Milojevic, M., Collet, J., Landoni, G., Castellà, M., Dunning, J., Guðbjartsson, T., Linker, N., Sandoval, E., et al. (2017) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezx314 · Cited by 402 · see citing works
Levy, J. H., Ageno, W., Chan, N., Crowther, M. A., Verhamme, P. B., & Weitz, J. I. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13227 · Cited by 377 · see citing works
Self-citationInterventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., Andrés, J. A. D., Deer, T. R., Rauck, R. L., & Huntoon, M. A. (2015) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 364 · see citing works
Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review
Byon, W., Merali, S. J., Boyd, R. A., & Frost, C. E. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00775-z · Cited by 356 · see citing works
Tomaselli, G. F., Mahaffey, K. W., Cuker, A. C., Dobesh, P. P., Doherty, J. U., Eikelboom, J. W., Florido, R., Hucker, W. J., Mehran, R., Messe, S. R., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.1085 · Cited by 344 · see citing works
Self-citationMajeed, A., Ågren, A., Holmström, M., Bruzelius, M., Chaireti, R., Odeberg, J., Hempel, E.-L., Magnusson, M., Frisk, T., & Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-05-782060 · Cited by 327 · see citing works
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.03.017 · Cited by 312 · see citing works
Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
Connolly, S. J., Sharma, M., Cohen, A. T., Demchuk, A. M., Członkowska, A., Lindgren, A. G., Molina, C. A., Bereczki, D., Toni, D., Seiffge, D. J., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313040 · Cited by 284 · see citing works
Self-citation2020 ACC/AHA guideline for the management of patients with valvular heart disease
Otto, C. M., Nishimura, R. A., Bonow, R. O., Carabello, B. A., Erwin, J. P., Gentile, F., Jneid, H., Krieger, E. V., Mack, M., McLeod, C., et al. (2021) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.04.002 · Cited by 279 · see citing works
Macle, L., Cairns, J. A., Leblanc, K., Tsang, T. S. M., Skanes, A. C., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 271 · see citing works
Self-citationRaval, A. N., Cigarroa, J. E., Chung, M. K., Díaz‐Sandoval, L. J., Diercks, D., Piccini, J. P., Jung, H. S., Washam, J. B., Welch, B. G., Zazulia, A. R., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000477 · Cited by 249 · see citing works
Intagliata, N. M., Henry, Z. H., Maitland, H. S., Shah, N. L., Argo, C. K., Northup, P. G., & Caldwell, S. H. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-015-4012-2 · Cited by 246 · see citing works
Management of Intracerebral Hemorrhage
Schrag, M., & Kirshner, H. S. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.066 · Cited by 244 · see citing works
Andrade, J. G., Verma, A., Mitchell, L. B., Parkash, R., Leblanc, K., Atzema, C. L., Healey, J. S., Bell, A., Cairns, J. A., Connolly, S. J., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.08.026 · Cited by 235 · see citing works
Self-citationApixaban Pharmacokinetics at Steady State in Hemodialysis Patients
Mavrakanas, T. A., Samer, C. F., Nessim, S. J., Frisch, G., & Lipman, M. L. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016090980 · Cited by 229 · see citing works
Peri‐operative management of anticoagulation and antiplatelet therapy
Keeling, D. M., Tait, R. C., & Watson, H. G. (2016) · British Journal of Haematology · doi:10.1111/bjh.14344 · Cited by 227 · see citing works
Douxfils, J., Adcock, D. M., Bates, S. M., Favaloro, E. J., Gouin‐Thibault, I., Guillermo, C., Kawai, Y., Lindhoff‐Last, E., Kitchen, S., & Gosselin, R. C. (2021) · Thrombosis and Haemostasis · doi:10.1055/a-1450-8178 · Cited by 212 · see citing works
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation
Chiang, C., Okumura, K., Zhang, S., Chao, T., Siu, C., Lim, T. W., Saxena, A., Takahashi, Y., & Teo, W. S. (2017) · Journal of Arrhythmia · doi:10.1016/j.joa.2017.05.004 · Cited by 198 · see citing works
Peden, C. J., Aggarwal, G., Aitken, R., Anderson, I. D., Foss, N. B., Cooper, Z. R., Dhesi, J. K., French, W. B., Grant, M. C., Hammarqvist, F., et al. (2021) · World Journal of Surgery · doi:10.1007/s00268-021-05994-9 · Cited by 191 · see citing works
Intagliata, N. M., Argo, C. K., Stine, J. G., Lisman, T., Caldwell, S. H., Violi, F., & Disease, O. B. O. T. F. O. T. 7. I. C. I. L. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1666861 · Cited by 180 · see citing works
Li, Q., Yakhkind, A., Alexandrov, A. W., Alexandrov, A. V., Anderson, C. S., Dowlatshahi, D. D., Frontera, J. A., Hemphill, J. C., Ganti, L., Kellner, C. P., et al. (2023) · Stroke · doi:10.1161/strokeaha.123.043033 · Cited by 175 · see citing works
Current management of spontaneous intracerebral haemorrhage
Dastur, C. K., & Yu, W. (2017) · Stroke and Vascular Neurology · doi:10.1136/svn-2016-000047 · Cited by 173 · see citing works
Montaño, A., Hanley, D. F., & Hemphill, J. C. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64034-5.00019-5 · Cited by 173 · see citing works
Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors
Milling, T. J., Middeldorp, S., Xu, L., Koch, B., Demchuk, A. M., Eikelboom, J. W., Verhamme, P. B., Cohen, A. T., Beyer‐Westendorf, J., Gibson, C. M., et al. (2023) · Circulation · doi:10.1161/circulationaha.121.057844 · Cited by 170 · see citing works
Self-citationNarouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., Andrés, J. A. D., Deer, T. R., Rauck, R. L., & Huntoon, M. A. (2017) · Regional Anesthesia & Pain Medicine · doi:10.1097/aap.0000000000000700 · Cited by 168 · see citing works
Eikelboom, J. W., Quinlan, D. J., van Ryn, J., & Weitz, J. I. (2015) · Circulation · doi:10.1161/circulationaha.115.019628 · Cited by 162 · see citing works
Outcome of intracerebral hemorrhage associated with different oral anticoagulants
Wilson, D., Seiffge, D. J., Traenka, C., Basir, G. S., Purrucker, J. C., Rizos, T., Sobowale, O. A., Sallinen, H., Yeh, S., Wu, T. Y., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003886 · Cited by 155 · see citing works
Christensen, H., Cordonnier, C., Kõrv, J., Lal, A., Ovesen, C., Purrucker, J. C., Toni, D., & Steiner, T. (2019) · European Stroke Journal · doi:10.1177/2396987319849763 · Cited by 155 · see citing works
Zirlik, A., & Bode, C. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1446-0 · Cited by 151 · see citing works
Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban
Ansell, J., Bakhru, S., Laulicht, B., Steiner, S. S., GROSSO, M. A., Brown, K. D., Dishy, V., Lanz, H., Mercuri, M. F., Noveck, R. J., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0224 · Cited by 146 · see citing works
Reversal agents for non-vitamin K antagonist oral anticoagulants
Levy, J. H., Douketis, J. D., & Weitz, J. I. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.223 · Cited by 140 · see citing works
Chiang, C., Wu, T.-J., Ueng, K.-C., Chao, T., Chang, K., Wang, C.-C., Lin, Y., Yin, W., Kuo, J., Lin, W., et al. (2016) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2016.10.005 · Cited by 138 · see citing works
Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers
Bhatt, D. L., Pollack, C. V., Weitz, J. I., Jennings, L. K., Xu, S., Arnold, S. E., Umstead, B. R., Mays, M. C., & Lee, J. S. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901778 · Cited by 138 · see citing works
JCS/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias
Ono, K., Iwasaki, Y., Akao, M., Ikeda, T., Ishii, K., Inden, Y., Kusano, K., Kobayashi, Y., Koretsune, Y., Sasano, T., et al. (2022) · Circulation Journal · doi:10.1253/circj.cj-20-1212 · Cited by 132 · see citing works
Advances in Therapeutic Approaches for Spontaneous Intracerebral Hemorrhage
Al‐Kawaz, M., Hanley, D. F., & Ziai, W. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00902-w · Cited by 129 · see citing works
Spontaneous Intracerebral Hemorrhage: Management
Kim, J. Y., & Bae, H. (2017) · Journal of Stroke · doi:10.5853/jos.2016.01935 · Cited by 127 · see citing works
Hematoma Expansion in Intracerebral Hemorrhage: An Update on Prediction and Treatment
Li, Z., You, M., Long, C., Bi, R., Xu, H., He, Q., & Hu, B. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00702 · Cited by 127 · see citing works
Piran, S., Khatib, R., Schulman, S., Majeed, A., Holbrook, A. M., Witt, D. M., Wiercioch, W., Schünemann, H. J., & Nieuwlaat, R. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018024133 · Cited by 126 · see citing works
Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants
Eikelboom, J. W., Kozek‐Langenecker, S. A., Exadaktylos, A., Bátorová, A., Boda, Z., Christory, F., Gornik, I., Kėkštas, G., Kher, A., Komadina, R., et al. (2017) · British Journal of Anaesthesia · doi:10.1016/j.bja.2017.11.082 · Cited by 125 · see citing works
Adeboyeje, G., Sylwestrzak, G., Barron, J. J., White, J., Rosenberg, A., Abarca, J., Crawford, G., & Redberg, R. F. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.9.968 · Cited by 121 · see citing works
Andexanet Alfa: First Global Approval
Heo, Y. (2018) · Drugs · doi:10.1007/s40265-018-0940-4 · Cited by 119 · see citing works
Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants
Kanuri, S. H., & Kreutz, R. P. (2019) · Journal of Personalized Medicine · doi:10.3390/jpm9010007 · Cited by 119 · see citing works
Ntaios, G., Papavasileiou, V., Diener, H.-C., Makaritsis, K. P., & Michel, P. (2017) · International Journal of Stroke · doi:10.1177/1747493017700663 · Cited by 117 · see citing works
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy
Lópes, R. D., Guimarães, P. O., Kolls, B. J., WOJDYLA, D. M., Bushnell, C., Hanna, M., Easton, J. D., Thomas, L. E., Wallentin, L. C., Al‐Khatib, S. M., et al. (2017) · Blood · doi:10.1182/blood-2016-08-731638 · Cited by 113 · see citing works
Perioperative management of patients on direct oral anticoagulants
Dubois, V., Dincq, A.-S., Douxfils, J., Ickx, B., Samama, C. M., Dogné, J., Gourdin, M. J., Châtelain, B., Mullier, F., & Lessire, S. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0137-1 · Cited by 113 · see citing works
Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting
Ghadimi, K., Levy, J. H., & Welsby, I. J. (2016) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001188 · Cited by 111 · see citing works
Evolving Treatments for Arterial and Venous Thrombosis
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 110 · see citing works
Ruff, C. T., Giugliano, R. P., & Antman, E. M. (2016) · Circulation · doi:10.1161/circulationaha.116.021831 · Cited by 106 · see citing works
Synthetic oligosaccharides can replace animal-sourced low–molecular weight heparins
Xu, Y., Chandarajoti, K., Zhang, X., Pagadala, V., Dou, W., Hoppensteadt, D., Sparkenbaugh, E., Cooley, B. C., Daily, S., Key, N. S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5954 · Cited by 106 · see citing works
New developments in anticoagulants: Past, present and future
Weitz, J. I., & Harenberg, J. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0807 · Cited by 105 · see citing works
Chao, T., Joung, B., Takahashi, Y., Lim, T. W., Choi, E., Chan, Y., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K., et al. (2021) · Journal of Arrhythmia · doi:10.1002/joa3.12652 · Cited by 100 · see citing works
The Role of TEG and ROTEM in Damage Control Resuscitation
Brill, J. B., Brenner, M., Duchesne, J., Roberts, D., Ferrada, P., Horer, T., Kauvar, D. S., Khan, M. A., Kirkpatrick, A., Ordoñez, C. A., et al. (2021) · Shock · doi:10.1097/shk.0000000000001686 · Cited by 96 · see citing works
Deer, T. R., Narouze, S., Provenzano, D. A., Pope, J. E., Falowski, S. M., Russo, M. A., Benzon, H. T., Slavin, K. V., Pilitsis, J. G., Alò, K. M., et al. (2017) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12542 · Cited by 92 · see citing works
Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease
Jain, N., & Reilly, R. F. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02170218 · Cited by 91 · see citing works
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 90 · see citing works
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 89 · see citing works
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience
Eikelboom, J. W., & Merli, G. J. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.003 · Cited by 89 · see citing works
Rose, D., & Bar, B. (2018) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2018.04.004 · Cited by 84 · see citing works
Tummala, R., Kavtaradze, A., Gupta, A., & Ghosh, R. K. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.03.056 · Cited by 82 · see citing works
A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery
Milling, T. J., & Ziebell, C. M. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.03.004 · Cited by 82 · see citing works
Emergency Reversal of Anticoagulation
Yee, J., & Kaide, C. G. (2019) · Western Journal of Emergency Medicine · doi:10.5811/westjem.2018.5.38235 · Cited by 81 · see citing works
Ammar, A. A., Ammar, M. A., Owusu, K. A., Brown, S. C., Kaddouh, F., Elsamadicy, A. A., Acosta, J., & Falcone, G. J. (2021) · Neurocritical Care · doi:10.1007/s12028-020-01161-5 · Cited by 79 · see citing works
Bliden, K. P., Chaudhary, R., Mohammed, N., Muresan, A. A., Lopez-Espina, C. G., Cohen, E., Raviv, G., Doubleday, M., Zaman, F., Mathew, B., et al. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-017-1477-1 · Cited by 78 · see citing works
Direct oral anticoagulants versus warfarin: is new always better than the old?
Burn, J., & Pirmohamed, M. (2018) · Open Heart · doi:10.1136/openhrt-2017-000712 · Cited by 77 · see citing works
Tzeis, S. E., Gerstenfeld, E. P., Kalman, J. M., Saad, E., Shamloo, A. S., Andrade, J. G., Barbhaiya, C. R., Baykaner, T., Bovéda, S., Calkins, H. G., et al. (2024) · Journal of Arrhythmia · doi:10.1002/joa3.13082 · Cited by 76 · see citing works
Treatment of Venous Thromboembolism With New Anticoagulant Agents
Becattini, C., & Agnelli, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.072 · Cited by 75 · see citing works
Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage
Kuramatsu, J. B., Sembill, J. A., & Huttner, H. B. (2019) · Critical Care · doi:10.1186/s13054-019-2492-8 · Cited by 75 · see citing works
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Siegal, D. M., Lu, G., Leeds, J. M., Karbarz, M. J., Castillo, J., Mathur, V. S., Hutchaleelaha, A., Sinha, U., Kitt, M. M., McClure, M. W., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007112 · Cited by 74 · see citing works
Self-citationReversal of direct oral anticoagulants: guidance from the SSC of the ISTH
Levy, J. H., Shaw, J. R., Castellucci, L. A., Connors, J. M., Douketis, J. D., Lindhoff‐Last, E., Rocca, B., Samama, C. M., Siegal, D. M., & Weitz, J. I. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.07.009 · Cited by 73 · see citing works
Self-citationAdherence to long‐term anticoagulation treatment, what is known and what the future might hold
Bartoli-Abdou, J., Auyeung, V., Patel, J. P., & Arya, R. (2016) · British Journal of Haematology · doi:10.1111/bjh.14134 · Cited by 73 · see citing works
Direct oral anticoagulants: a review on the current role and scope of reversal agents
Chaudhary, R., Sharma, T., Garg, J., Sukhi, A., Bliden, K. P., Tantry, U. S., Turagam, M. K., Lakkireddy, D., & Gurbel, P. A. (2019) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-019-01954-2 · Cited by 72 · see citing works
Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants
Touzé, E., Gruel, Y., Gouin‐Thibault, I., de Maistre, E., Susen, S., Siè, P., & Derex, L. (2018) · European Journal of Neurology · doi:10.1111/ene.13582 · Cited by 71 · see citing works
Zeeshan, M., Jehan, F., O’Keeffe, T., Khan, M., Zakaria, E. R., Hamidi, M., Gries, L. M., Kulvatunyou, N., & Joseph, B. A. (2018) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000001995 · Cited by 71 · see citing works
Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass
Gunaratne, R., Kumar, S., Frederiksen, J. W., Stayrook, S. E., Lohrmann, J., Perry, K., Bompiani, K. M., Chabata, C. V., Thalji, N. K., Ho, M., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4153 · Cited by 71 · see citing works
- Authors
- Siegal, D. M., Curnutte, J. T., Connolly, S. J., Lu, G., Conley, P. B., Wiens, B. L., Mathur, V. S., Castillo, J., Bronson, M. D., Leeds, J. M., Mar, F. A., Gold, A., & Crowther, M. A.
- Affiliations
- Population Health Research Institute (CA)
- Portola Pharmaceuticals (United States) (US)
- McMaster University (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-12-17
- Volume
- 373
- Issue
- 25
- Pages
- 2413-2424
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2174386486
- Cited by
- 1,047
- References
- 22
- Citations by year
- 2026: 21 · 2025: 34 · 2024: 48 · 2023: 56 · 2022: 44 · 2021: 57 · 2020: 91 · 2019: 126 · 2018: 133 · 2017: 175 · 2016: 249 · 2015: 11 · 2013: 1
- FWCI
- 137.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Keywords
- andexanet alfa, factor Xa inhibitors, apixaban, rivaroxaban, anticoagulant reversal, bleeding complications, anti-Xa activity, thrombin generation, unbound drug concentration, D-dimer, prothrombin fragments, older adults, drug safety, pharmacokinetics, pharmacodynamics, thromboprophylaxis, thrombolysis
- MeSH terms
- Rivaroxaban, Administration, Oral, Aged, Antidotes, Blood Coagulation, Double-Blind Method, Female, Hemorrhage, Humans, Male, Middle Aged, Peptide Fragments, Protein Precursors, Prothrombin, Pyrazoles, Pyridones, Recombinant Proteins, Factor Xa, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
